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Diameter-dependent release of a cisplatin
pro-drug from small and large functionalized
carbon nanotubes†
Laura Muzi,a,b Cécilia Ménard-Moyon,a Julie Russier,a Jian Li,c Chee Fei Chin,d
Wee Han Ang,d,e Giorgia Pastorin,*c,e Gianfranco Risuleo*b and Alberto Bianco*a
The use of platinum-based chemotherapeutic drugs in cancer therapy still suﬀers from severe disadvan-
tages, such as lack of appropriate selectivity for tumor tissues and insurgence of multi-drug resistance.
Moreover, drug eﬃcacy can be attenuated by several mechanisms such as premature drug inactivation,
reduced drug uptake inside cells and increased drug eﬄux once internalized. The use of functionalized
carbon nanotubes (CNTs) as chemotherapeutic drug delivery systems is a promising strategy to overcome
such limitations due to their ability to enhance cellular internalization of poorly permeable drugs and thus
increase the drug bioavailability at the diseased site, compared to the free drug. Furthermore, the possi-
bility to encapsulate agents in the nanotubes’ inner cavity can protect the drug from early inactivation and
their external functionalizable surface is useful for selective targeting. In this study, a hydrophobic
platinum(IV) complex was encapsulated within the inner space of two diﬀerent diameter functionalized
multi-walled CNTs (Pt(IV)@CNTs). The behavior of the complexes, compared to the free drug, was investi-
gated on both HeLa human cancer cells and RAW 264.7 murine macrophages. Both CNT samples
eﬃciently induced cell death in HeLa cancer cells 72 hours after the end of exposure to CNTs. Although
the larger diameter CNTs were more cytotoxic on HeLa cells compared to both the free drug and the
smaller diameter nanotubes, the latter allowed a prolonged release of the encapsulated drug, thus
increasing its anticancer eﬃcacy. In contrast, both Pt(IV)@CNT constructs were poorly cytotoxic on
macrophages and induced negligible cell activation and no pro-inﬂammatory cytokine production. Both
CNT samples were eﬃciently internalized by the two types of cells, as demonstrated by transmission
electron microscopy observations and ﬂow cytometry analysis. Finally, the platinum levels found in the
cells after Pt(IV)@CNT exposure demonstrate that they can promote drug accumulation inside cells in
comparison with treatment with the free complex. To conclude, our study shows that CNTs are promising
nanocarriers to improve the accumulation of a chemotherapeutic drug and its slow release inside tumor
cells, by tuning the CNT diameter, without inducing a high inﬂammatory response.
1. Introduction
Chemotherapy, either alone or in combination with surgery
and radiation therapy, is widely used to treat diﬀerent types of
cancer. However, limited drug solubility, rapid elimination
and lack of appropriate selectivity for tumor tissues, causing
severe side eﬀects, are some of the drawbacks faced by current
chemotherapeutics. Moreover, various cancers display both
intrinsic and acquired multidrug-resistance. This phenom-
enon can be ascribed to P-glycoprotein, an eﬄux pump able to
recognize and transport the drug out from the cell once inter-
nalized, therefore attenuating the drug-induced cytotoxic
eﬀect.1 Among all, Pt(II) cisplatin analogues, together with
carboplatin or oxaliplatin, have a central role in cancer
chemotherapy, including testicular, cervical, head and neck,
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ovarian and non-small-cell lung cancer.2 Pt(IV) complexes have
also been synthesized as inactive cisplatin prodrugs, which
can be converted to their active Pt(II) form upon cleavage of
the axial ligands.3 On the other hand, the poor specificity of
these drugs induces numerous side eﬀects, such as nephro-
toxicity, emetogenesis, ototoxicity and neurotoxicity, thus lim-
iting their applications.4 Cisplatin’s mechanism of action
involves the formation of DNA interstrand cross-links. Severe
cellular DNA damage disrupts the normal replication and tran-
scription processes activating the cell cycle checkpoint leading
to apoptosis.5 To make this possible, once internalized, cispla-
tin undergoes a series of aquation reactions. The active mono-
aquated form of cisplatin is a highly reactive species which
can be recognized by several endogenous nucleophiles, thus
making the drug potentially vulnerable and leading to prema-
ture cytoplasmic inactivation.6 Moreover, in some cancer cells,
reduction in drug accumulation is the main mechanism of cis-
platin resistance. In addition to an increased expression of
eﬄux pumps, the mechanism is also associated with the
downregulation of the plasma membrane copper transporter
CTR1 involved in cisplatin uptake. An increased DNA damage
tolerance and the loss of propagation of the DNA damage
signals to the apoptotic machinery are other downstream cellu-
lar resistance mechanisms to cisplatin.6–8
Nanomaterials can help in overcoming the limitations
described above, oﬀering great advantages to the delivery of
therapeutic molecules to the tumors. They can help the deliv-
ery of drugs with poor solubility and stability, reduce their
non-specific accumulation and toxicity, improve the pharmaco-
kinetics and bioavailability and increase local drug concen-
trations. As a whole eﬀect, they can enhance both drug
permeability and retention at the target tissue. Several nano-
carriers have been used for the delivery of platinum-based anti-
cancer drugs including liposomes, micelles, dendrimers,
polymeric nanoparticles and carbon nanotubes.9–11
CNTs are among the most attractive nanovectors under
investigation.12 Functionalized CNTs ( f-CNTs) have shown
great promise as tools for biomedical applications. This is due
to their well demonstrated ability to cross biological barriers
entering and accumulating inside cells.13,14 In addition, their
high surface area provides multiple attachment sites for mole-
cules and are in turn useful for selective targeting.15 In fact,
CNTs have been used as biosensors, as scaﬀolds for regenera-
tive medicine and as delivery systems of many bioactive mole-
cules, including various anti-cancer agents.16–19 Therapeutic
molecules can be either attached on the external CNT wall or
encapsulated within their inner cavity, thus protecting the
drug from premature inactivation and enabling the possibility
of controlled drug release.20 On the other hand, diﬀerent
approaches have been developed to make this material bio-
compatible and recently, it has been demonstrated that f-CNTs
can be degraded by oxidative enzymes.21
In this study, a hydrophobic Pt(IV) prodrug of cisplatin was
entrapped within the inner cavity of two diﬀerent diameter
fluorescently labeled multi-walled CNTs (MWCNTs) and the
complexes were tested for their activity on two diﬀerent cellu-
lar models. A number of studies on the eﬃcacy of cisplatin-
filled carbon-based nanomaterials, in particular single-walled
CNTs (SWCNTs), have been published.22–27 However, the
smaller diameter of SWCNTs allows encapsulating a lower
amount of drug molecules compared to MWCNTs. Further-
more, another advantage of our complexes is the use of a
prodrug, designed to achieve intracellular controlled release of
the cytotoxic Pt(II) species. In fact, upon chemical reduction by
endogenous reducing agents such as glutathione, the prodrug
can be released from the CNT cavity being converted into its
active hydrophilic Pt(II) form able to react with DNA.28 This
avoids a fast and premature drug release (unlike what happens
with cisplatin), preventing also its possible inactivation. Our
groups previously demonstrated that Pt(IV)@CNTs can signifi-
cantly enhance drug accumulation in some tissues after being
intravenously injected in mice without inducing any abnormal
inflammation. Moreover, both kidney and liver accumulation
were reduced thus decreasing eventual nephrotoxicity, a
typical side eﬀect of cisplatin.29 For a better understanding of
Pt(IV)@CNT complex activity, in the current study the cytotoxi-
city, the possible induction of a pro-inflammatory response
and the cellular uptake were investigated on human cancer
cells HeLa and murine macrophages RAW 264.7. The intra-
cellular platinum accumulation after exposure to diﬀerent
complexes was also explored. In addition, the eﬀect of the
MWCNT diameter on the release and activity of the Pt(IV)
prodrug was examined for the first time.
2. Results and discussion
2.1. Preparation of Pt(IV)@CNTs
Two types of MWCNTs with diﬀerent diameters and length dis-
tributions were used in this study. The CNT diameter distri-
butions are shown in Fig. 1A. MWCNTs (S-CNTs) from Nanocyl
company have an average external diameter and length of
10 nm (n = 178, σ = 2.8) and 1.5 µm, respectively. We also used
non-commercial MWCNTs (L-CNTs) with a bigger external
diameter (38 nm in average, n = 144, σ = 13.6) and a length
ranging from 200 nm to several microns. The average inner dia-
meter of S- and L-CNTs is 4 nm30 and 10 nm,29 respectively. To
reduce their length, both types of MWCNTs were treated under
acid conditions using a mixture of sulfuric and nitric acid
(3 : 1) under sonication (Scheme 1). The length distribution of
both types of MWCNTs after oxidation is shown in Fig. 1B: the
average length of shortened S- and L-CNTs is 274 nm (n = 222,
σ = 227) and 855 nm (n = 100, σ = 537), respectively. Both types
of MWCNTs have a similar aspect ratio in the range of 23–27.
To allow monitoring of the traﬃcking of MWCNTs upon
interactions with cells, we labeled the nanotubes with the fluo-
rescent probe cyanine 5 (Cy5). The synthetic strategy for the
derivatization of S-CNTs is shown in Scheme 1. We first deriva-
tized the oxidized S-CNTs 1 by amidation with Boc-mono-
protected diamine derivative 2, after activation of the carboxylic
groups using oxalyl chloride. The Boc protecting group was
cleaved using HCl in 1,4-dioxane. The Kaiser test was used to
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assess the amount of amino groups: 400 µmol per gram of
S-CNTs 4.31 The ammonium functions were derivatized with
Cy5 derivative 5 in the presence of O-(N-succinimidyl)-N,N,N′,N′-
tetramethyluronium tetrafluoroborate (TSTU) as the coupling
agent.32 According to the Kaiser test, the amine loading
drastically decreased (165 µmol g−1), which confirmed the
eﬃciency of the amidation reaction. We deduced that the level
of functionalization was 235 µmol of Cy5 per gram of S-CNTs
6. We followed a similar strategy to label the L-CNTs with Cy5.
Amino-L-CNTs S1 were prepared according to a protocol pre-
viously reported by our group.29 The amines were derivatized
with Cy5 derivative 5 using TSTU (Scheme S1†). After the reac-
tion, the Kaiser test decreased from 670 to 105 µmol g−1. Thus,
the Cy5 loading was 565 µmol per gram of L-CNTs S2.
2.2. Characterization of functionalized MWCNTs
The functionalized MWCNTs were characterized by Trans-
mission electron microscopy (TEM) and thermogravimetric
analysis (TGA). The TEM images of S-CNTs 4 and L-CNTs S1
are shown in Fig. 2A and 2B. The shortening of both types of
CNTs is clearly visible in comparison with pristine purified
S-CNTs and L-CNTs (Fig. S1†).
The TGA profiles of pristine purified S-CNTs, oxidized
S-CNTs 1, and S-CNTs 4 and 6 are displayed in Fig. 2C. As the
analyses were performed under an inert atmosphere, the
weight loss observed corresponds to the amount of functional
groups present on the nanotube surface. As expected, the pris-
tine purified S-CNTs show a negligible weight loss under these
conditions, while the weight loss gradually increases after each
step of derivatization, which shows successful functionali-
zation. The TGA of L-CNTs S2 in comparison with the precur-
sor L-CNTs is shown in Fig. S2.†
The Cy5-CNTs 6 and S3 were filled with platinum(IV)
prodrug S3 (Fig. S3†). The entrapment of the Pt(IV) complex
was performed according to the nano-extraction procedure we
Fig. 1 Histograms of the diameter of S- and L-CNTs (A) and length dis-
tribution of functionalized S- and L-CNTs (B). The diameter and length
were measured on hundreds of CNTs in TEM images.
Scheme 1 Functionalization of S-CNTs with cyanine 5.
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recently reported for the encapsulation of S3 in amino-CNTs
S1.29 The platinum content was determined using inductively
coupled plasma atomic emission spectrometry (ICP/AES). High
Pt(IV) levels were measured inside both types of CNTs: 37.3%
and 35.6% w/w of Pt(IV) for S-CNTs 6 and L-CNTs S2, respect-
ively. The Pt(IV)@CNTs 6 and S2 were characterized by high-
resolution TEM (HR-TEM) coupled to EDX (Fig. 3 and S4†).
The energy-dispersive X-ray spectroscopy (EDX) analyses were
performed at diﬀerent locations, either in the inner core of the
nanotubes or on their sidewall. We could observe the appear-
ance of the Pt M peak at 2.05 keV (Fig. 3A) when analyzing the
cavity of Pt(IV)@L-CNTs S2, while no significant amount of Pt
was detected in the sidewall (Fig. 3B). Similar results were also
obtained for Pt(IV)@S-CNTs 6, confirming that the majority of
Pt detected by EDX was found in the inner core of the nano-
tubes, which is indicative of a high entrapment eﬃciency.
2.3. Cellular viability
As a first step in our investigation, the cytotoxicity of the two
diﬀerent Pt(IV)@CNTs compared to the free drug was evaluated
in cells with diﬀerent characteristics and origin. For this
purpose, human cervix cancer cells HeLa (non-phagocytic) and
murine macrophages RAW 264.7 (phagocytic) were chosen. As
previously described, S- and L-CNTs diﬀer only in their dia-
meter and length, whereas they have similar aspect ratio and
drug loading. In an initial experiment, cells were incubated
with Pt(IV)@CNT complexes at Pt(IV) concentrations ranging
from 1 to 15 µM (HeLa) or from 0.5 to 10 µM (RAW 264.7) for
24 h. The corresponding amount of MWCNTs used was back-
calculated from the loading of the prodrug inside the tubes
(Table 1). As Pt(IV) loading inside S- and L-CNTs was rather
similar (37.3% and 35.6%, respectively), almost equal concen-
trations of the two CNT types were used. At the end of the incu-
bation, cellular viability was determined by flow cytometry.
Results are shown in Fig. 4 (where only live cells are reported)
and S5 (where also dead and pre-apoptotic cells are reported). In
the case of HeLa cells (Fig. 4A and S5A†), a concentration-depen-
dent cytotoxicity was observed with both CNT samples and also
the free drug. Furthermore, there was no significant diﬀerence
when comparing the free drug with Pt(IV)-@L-CNTs in the whole
concentration range. In contrast, both the free drug and the
larger CNTs were more cytotoxic than the smaller ones.
Fig. 2 TEM images of S-CNTs 4 (A) and L-CNTs S1 (B). TGA of pristine
S-CNTs, oxidized S-CNTs 1, S-CNTs 4 and 6 under N2 (C).
Fig. 3 HRTEM images and EDX spectra of Pt(IV)@L-CNTs S2 taken at
two diﬀerent locations (see red circles): in the cavity (A) and in the side-
wall (B). Scale bars correspond to 10 nm (A) and 5 nm (B).
Table 1 Concentrations of Pt(IV), Pt(IV)@S-CNTs and Pt(IV)@L-CNTs
used for the cell treatment. The corresponding MWCNT concentrations
were back-calculated from Pt(IV) loading inside MWCNTs
Pt(IV)
(μM)
Pt(IV)
(μg ml−1)
Pt(IV)@S-CNTs
(μg ml−1)
Pt(IV)@L-CNTs
(μg ml−1)
0.1 0.05 0.15 0.15
0.2 0.11 0.29 0.30
0.5 0.27 0.72 0.76
1 0.54 1.45 1.52
2 1.08 2.90 3.00
3.5 1.89 5.07 5.31
5 2.70 7.24 7.58
7.5 4.05 10.86 11.38
10 5.40 14.48 15.17
15 8.10 21.75 22.80
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This first experiment allowed us to demonstrate the role of
MWCNT diameter in the release of the embedded drug. As pre-
viously described, the hydrophobic Pt(IV) prodrug is selectively
released by chemical reduction and hydrophobicity reversal
from the inner cavity of CNTs by reducing agents, being con-
verted into its active Pt(II) species.28 In view of this, one
hypothesis to explain the diﬀerent eﬃcacy of the two CNT
samples could be a reduced accessibility to the intracellular
reducing agents, such as glutathione, in the case of MWCNTs
with smaller diameter compared to the larger tubes. Conse-
quently, the active form of the drug could be released more
slowly by S-CNTs compared to L-CNTs, thus explaining their
lower cytotoxicity after 24 h.
On the other hand, RAW 264.7 cells displayed a general
higher sensitivity to the samples compared to HeLa cells. In
fact, the same dose-dependent cytotoxicity but at lower concen-
trations was observed in RAW 264.7 cells (Fig. 4B and S5B†).
Moreover, the free drug was significantly more eﬀective than
both Pt(IV)@L-CNTs and Pt(IV)@S-CNTs. This is consistent
with the results obtained after exposure to 20% DMSO used as
the positive control. In fact, the residual cellular viability was
about 50% in the case of HeLa and 0% in RAW 264.7,
suggesting an overall higher sensitivity of the murine macro-
phages compared to the other cell line. Despite this, as
observed in HeLa cells, Pt(IV)@S-CNTs were again less cytotoxic
compared to Pt(IV)@L-CNTs, a result consistent with the pre-
vious hypothesis. It has to be noticed that the observed toxicity
on both cell types was only due to the Pt(IV)@CNT hybrid since
the empty CNTs caused no alteration of HeLa and RAW 264.7
cell viability at the same corresponding concentrations (shown
in µg ml−1 in Fig. S5A and B†). This observation is important,
since CNT’s intrinsic cytotoxicity is always an important issue
to be investigated to avoid unexpected toxicological eﬀects in
normal cell populations that are absolutely unwanted in the
case of an anticancer therapy.33,34
Similar results were obtained when a 48 h treatment
(Fig. S6A and B†) and a time course experiment (Fig. S7A and
B†) were performed on the same cell types.
As a slower release of the encapsulated drug was hypo-
thesized in the case of S-CNTs compared to L-CNTs, long-term
cell viability experiments were performed. For this purpose,
both HeLa and RAW 264.7 cells were incubated with the CNTs
at concentrations ranging from 0.1 to 2 µM Pt(IV) for 6 hours
before the medium was renewed with fresh medium and cells
were kept in culture for further 72 h. In this experiment, HeLa
cells (Fig. 5A and S8A†) began to show a significant mortality
compared to the control already at 0.2 µM Pt(IV) concentration
for both CNT samples. In this case, Pt(IV)@S-CNTs’ cytotoxicity
was comparable to the free drug although they were poorly
eﬀective after 24 h even at higher concentrations. The gain of
function of Pt(IV)@S-CNTs after a relatively long period of time
is fully consistent with our hypothesis. In fact, the intracellular
reducing agents could have had more time to induce the
release of the drug from the small diameter CNTs, making the
Pt(IV)@S-CNTs more cytotoxic. On the other hand, the larger
CNTs induced higher cellular mortality in comparison with
both the free drug (from 0.5 to 1 µM) and the smaller ones
(from 0.5 to 2 µM) even though they displayed the same cyto-
toxicity as the free drug in the previous experiment. This again
reinforces our explanation. In contrast to the first experiment,
the two CNT samples but also the free drug displayed a negli-
gible cytotoxicity on RAW 264.7 cells in comparison with the
HeLa response (Fig. 5B and S8B†). In fact, the residual viability
after the treatment with all the conjugates was not less than
75% up to a drug concentration of 1 µM for both the free drug
and CNTs. In all the concentration ranges, the free drug was
more cytotoxic than the Pt(IV)@CNTs and there was no diﬀer-
ence in the eﬀect between the two CNT types. This result could
be explained by a recovery of the murine macrophages after
relatively short exposure to low concentrations of the conju-
gates, contrarily to HeLa cells, while continuous exposure
to high doses of the complexes for 24 h induced severe
cytotoxicity (Fig. 4B and S5B†). Similar to the first cell viability
experiments, no reduction in cell viability was observed
in both cell lines after exposure to the empty CNTs (Fig. S8A
and B†).
Fig. 4 Flow cytometry analysis of cellular viability in HeLa cells (A) and RAW 264.7 cells (B) exposed to diﬀerent concentrations of Pt(IV)@CNTs for
24 h. AnnV−/PI− live cells are shown in this graph. Two-way ANOVA followed by Bonferroni’s post-test was performed to determine the statistical
diﬀerences versus control cells and to compare the two CNT samples with each other and with Pt(IV) (*p < 0.05; **p < 0.01; ***p < 0.001).
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The results obtained in the cell viability experiments
demonstrate the eﬃcacy of both Pt(IV)@CNT complexes and
suggest their possible use as nanovectors for anticancer drugs.
Moreover, as already mentioned, one of the advantages of our
complexes is the use of a platinum(IV) prodrug that can be
reduced to release the cytotoxic compound cisplatin upon
entry into the cells. The advantages of Pt(IV)@CNT complexes
compared to Pt(II)@CNT, leveraging on the greater aqueous
stability of Pt(IV) prodrugs, has already been demonstrated by
the group of Lippard.23,24 In their previous reports, the Pt(IV)
prodrug was non-covalently linked on the external surface of
CNTs while in our work, the drug was entrapped within the
inner cavity of CNTs. This strategy of hydrophobic entrapment
shields the prodrug from premature inactivation6 and enables
controlled drug release by reduction, contrary to Pt(II) com-
plexes that are rapidly extruded from the cavity.28 In this
report, we demonstrated that the diameter of CNT plays an
important role in determining the rate of drug release and
directly aﬀects the eﬃcacy of the Pt(IV)@CNT construct. There-
fore, the CNT diameter should be taken into account in the
design and fine-tuning of these delivery vectors.
2.4. Cellular activation and cytokine determination
Avoiding inflammation is important, especially in cancer
therapy, where it can also play decisive roles at diﬀerent stages
of tumors and aﬀect responses to therapy.35,36 Since the induc-
tion of a pro-inflammatory response is an important issue of
investigation in the case of CNTs,37,38 cellular activation and
cytokine production by RAW 264.7 macrophages were explored
after exposure to all CNT samples. Macrophages were chosen
since they can be considered the primary sentinels of our body
not only to infectious organisms but also to exogenous
materials.39 For the first purpose, CD86 expression was chosen
as readout since this molecule is expressed by this cell popu-
lation upon activation.40 RAW 264.7 cells were treated with
diﬀerent concentrations of CNTs as previously described for
the cellular viability experiments (from 0.5 to 10 µM for 24 h
or from 0.1 to 2 µM for 6 h followed by a further 72 h cell
growth). CD86 expression on live cell gated population was
then measured by flow cytometry (Fig. 6A and B). After 24 h, a
significant increase in CD86 expression compared to both the
control and free drug was observed for the two types of CNTs
from a Pt(IV) concentration of 3.5 µM. Moreover, at this con-
centration, a major activation in the case of Pt(IV)@L-CNTs was
observed compared to Pt(IV)@S-CNTs. This behavior was not
measured at higher concentrations. In fact, while in the case
of S-CNTs CD86 expression followed a concentration-depen-
dent trend, CD86 levels decreased as the concentration of the
L-CNTs increased. This can be explained by the fact that
L-CNTs promoted higher cell mortality at a drug concentration
higher than 3.5 µM compared to the smaller tubes (Fig. 4B).
Therefore, the observed reduction of CD86 expression could be
due to the death of highly activated cells that were conse-
quently not detected. On the other hand, while the cytotoxicity
experiments showed an increased responsiveness of HeLa
cells to low Pt(IV)@CNT concentrations 72 h after 6 h
exposure (Fig. 5A), only a slight RAW 264.7 activation (*p <
0.05) at the highest Pt(IV)@CNT doses was observed (Fig. 6B).
Furthermore, there was no diﬀerence between the two CNT
types.
In order to further investigate the macrophage activation
profile in response to the conjugates, the cell culture super-
natants were collected from the previous experiments on RAW
264.7 macrophages and the levels of two pro-inflammatory
cytokines (IL6 and TNF α) were determined by ELISA. After a
24 hour treatment, no IL6 production was detected in cell
supernatants (Fig. 7A). In contrast, the TNF α secretion started
to arise significantly compared to the control from a 3.5 µM
Pt(IV) concentration in the case of L-CNTs (Fig. 7B). A minor
eﬀect on TNF α production was detected after treatment with
Pt(IV)@S-CNTs. In fact a significant diﬀerence between the two
types of nanotubes, starting from 5 µM Pt(IV), could be
Fig. 5 Flow cytometry analysis of cellular viability in HeLa cells (A) and RAW 264.7 cells (B) exposed to diﬀerent concentrations of Pt(IV)@CNTs for
6 h and allowed to grow for further 72 h. AnnV−/PI− live cells are shown in this graph. Two-way ANOVA followed by Bonferroni’s post-test was per-
formed to determine the statistical diﬀerences versus control cells and to compare the two CNT samples with each other and with Pt(IV) (*p < 0.05;
**p < 0.01; ***p < 0.001).
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observed. This is consistent with the previous result obtained
for RAW 264.7 cell activation. Before the cells start to display
a high mortality rate, we could observe a more important
increase in CD86 levels concerning the largest CNTs in com-
parison with the smaller tubes (Fig. 6A). On the other hand,
neither IL6 nor TNF α production was detected 72 hours after
the 6 hour cellular exposure to the diﬀerent complexes at con-
centrations ranging from 0.1 to 2 µM Pt(IV) (Fig. 7C and D).
This experimental observation is again consistent with the
results obtained previously (Fig. 6B), where only a slight
macrophage activation was observed. We can also exclude an
intrinsic MWCNT pro-inflammatory action41 because no eﬀect
on cellular activation or cytokine production was observed
after exposure to both the empty CNTs (Fig. S9†).
Taken together the results on cellular activation and cyto-
kine production encourage their use as nanovectors for cancer
therapy. Obviously, as is the case of any other type of drug,
safety is dependent on Pt(IV)@CNT concentrations.
Fig. 7 Cytokine production by RAW 264.7. IL6 (A) and TNF α (B) levels were determined after incubation with diﬀerent concentrations of Pt(IV)-
@CNTs for 24 h or after the cells were grown for further 72 h after a 6 h treatment (C and D for IL6 and TNF α, respectively). Two-way ANOVA fol-
lowed by Bonferroni’s post-test was performed to determine the statistical diﬀerences versus control cells and to compare the two Pt(IV)@CNT
samples with each other and with Pt(IV) (*p < 0.05; **p < 0.01; ***p < 0.001).
Fig. 6 Flow cytometry analysis of CD86 expression in RAW 264.7 exposed to diﬀerent concentrations of Pt(IV)@CNTs for 24 h (A) or 6 h and allowed
to grow for further 72 h (B). Two-way ANOVA followed by Bonferroni’s post-test was performed to determine the statistical diﬀerences versus
control cells and to compare the two Pt(IV)@CNT samples with each other and with Pt(IV) (*p < 0.05; **p < 0.01; ***p < 0.001).
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2.5. Cellular uptake
The results obtained with the cell viability experiments evi-
denced that the Pt(IV)@CNTs can preserve the cytotoxic activity
of the encapsulated Pt(IV) prodrug. In fact, upon cellular
exposure to the complexes, a reduction in cancer cell viability
was observed and it was comparable to the free drug, or even
increased in the case of Pt(IV)@L-CNTs (Fig. 5A). These results
suggested eﬃcient drug transport inside the cells and thus the
cellular internalization of both CNT complexes. To confirm
and visualize the CNT cellular uptake and possibly identify its
mechanisms, HeLa or RAW 264.7 cells were exposed to 10 µg
ml−1 of S- or L-CNTs for 6 h and the samples were processed
for TEM observations. Both CNT types were found inside the
human and murine cells, thus confirming their cellular
uptake (Fig. 8). In more detail, aggregation of CNTs inside vesi-
cles can be observed in all cases. This suggests an endocytic
(HeLa) or phagocytic (RAW 264.7) internalization pathway.42,43
It was also possible to identify some CNTs free into the cyto-
plasm. The latter observation is consistent with the previously
reported ability of CNTs to penetrate the cells by passive
diﬀusion as nanoneedles.42 In fact, upon inhibition of energy-
dependent internalization pathways, CNTs can be still interna-
lized by diﬀerent types of cells, as has been reported in pre-
vious work performed in our laboratories.43 On the other
hand, the free CNTs could be the result of endosome rupture.
In Fig. 8, a single CNT outside the endosome is evidenced by a
red arrow. Such behavior is particularly relevant, as nano-
materials’ ability to escape from the endolysosomal network
could facilitate the drug access to its target.44 No CNTs were
found in the nucleus of the two cell types. Despite this, the
drug was able to reach the nucleus and exert its function
blocking DNA replication5 as evidenced by the cellular viability
experiments. Besides the nuclear DNA, the free drug could
have triggered apoptosis also by aﬀecting the mitochondrial
DNA or by other mechanisms, such as damage of cytoplasmic
proteins or of the cytoskeleton.45 A model for the Pt(IV)@CNT
activity mechanism could first consist of their internalization
by both passive diﬀusion or endocytosis/phagocytosis. The
internalized CNTs could be then transported throughout the
endolysosomal pathway, subsequently escaping from these
compartments and slowly releasing the Pt(II) active form of the
drug within the cytoplasm.28 Finally, the free drug translocates
into the nucleus or to the mitochondrion exerting its cytotoxic
function. Incubating the cells with the same concentration of
Pt(IV)@CNTs for 6 h, similar results were obtained (data not
shown). Finally, the same TEM observations were carried out
after an incubation of 24 hours with Pt(IV)@CNTs. In this case,
a strong impairment of the general cellular structure due to
the transported drug eﬀect could be observed. Some examples
are reported in Fig. S10,† in which the cytoplasm of both cell
lines shows a wide presence of vacuoles and lysis residues. The
cellular uptake of Pt(IV)@CNTs was also followed by flow cyto-
metry thanks to the functionalization with the Cy5 fluorophore
(Fig. S11†). A fluorescence shift of HeLa (Fig. S11A†) or RAW
264.7 (Fig. S11B†) cell populations (corresponding to the Cy5
on the CNT surface) in comparison with the control was
observed, thus confirming their intracellular uptake. We can
assert that only a negligible amount of fluorescence could be
derived from the CNTs interacting with the cellular surface
as the samples were extensively washed before the analysis.
2.6. Analysis of the cellular platinum content
Flow cytometry analysis did not allow for a precise quantifi-
cation of Pt(IV)@CNTs inside the cells as the occurrence of
Fig. 8 TEM images of HeLa and RAW 264.7 incubated with the diﬀerent S- and L-CNTs (10 μg ml−1) for 6 h. The dotted areas in the top images are
enlarged in the respective bottom pictures.
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fluorescent quenching phenomena by CNTs could not be
excluded.46
For this reason we used ICP/AES to quantitatively analyze
the cellular content of platinum in HeLa and RAW 264.7 macro-
phages after 6 h exposure to 1 µM of both free Pt(IV) and Pt(IV)-
@CNT samples. It is important to mention that almost equal
concentrations of the two CNT types were utilized, as Pt(IV)
loading inside S- and L-CNTs was rather similar (Table 1). As
shown in Fig. 9A and B, an increase in the cellular platinum
content (both entrapped or released) compared to the free
drug could be observed for both CNT conjugates in the two
cell lines. In particular, the amount of platinum inside both
HeLa and the macrophages was about two times higher com-
pared to the free drug when the cells were exposed to Pt(IV)-
@S-CNTs. Concerning Pt(IV)@L-CNTs, the increase in the
intracellular drug accumulation compared to free Pt(IV) was
again more evident. In fact the platinum amount found inside
HeLa and RAW 264.7 cells was about three and four times
higher, respectively, than the free drug. Such results allow also
quantifying the CNT cell internalization. Interestingly, not a
great diﬀerence in the ability to internalize the complexes
between HeLa and RAW 264.7 cells was observed. In fact, as
macrophages are phagocytic cells, a major CNT uptake com-
pared to HeLa cells was expected. This was not the case,
demonstrating the ability of non-phagocytic cells to internalize
a considerable amount of Pt(IV)@CNTs by endocytosis or by
passive diﬀusion.43 On the other hand, L-CNTs were able to
enter both cell types more eﬃciently as compared to S-CNTs;
this result is consistent with their higher cytotoxicity after
24 hours (Fig. 4A). However, although less internalized, Pt(IV)-
@S-CNTs showed a cytotoxicity comparable to Pt(IV)@L-CNTs
in HeLa cells during the long-term cell viability experiment
(Fig. 5A). The latter observation evidences how the slower Pt(IV)
release by CNTs having a smaller diameter could be advan-
tageous to achieve an enhanced long-lasting cytotoxicity
against tumor cells, compared to CNTs with a larger diameter.
The results obtained by the cell uptake experiments are
encouraging, given the well-documented problems in cisplatin
cancer therapy. In fact, despite being one of the most potent
antitumor agents known, cisplatin’s decreased intracellular
accumulation is one of the main mechanisms of resistance to
the drug.2,6 The results show that our Pt(IV)@CNT complexes
could promote drug accumulation inside the cells. This,
together with the slow drug release achieved by using S-CNTs
as Pt(IV) carriers, could result in an enhanced drug cytotoxicity
and retention in cancer cells compared to the free drug.
3. Conclusion
In this study, a hydrophobic Pt(IV) prodrug of cisplatin was
entrapped within the cavity of two functionalized MWCNTs
having diﬀerent inner diameters. The complexes were tested
for their activity on two diﬀerent cellular models. The activity
of the entrapped drug was preserved in both conjugates and
the role of the CNT diameter in the release of the encapsulated
drug was demonstrated. Both Pt(IV)@CNT complexes induced
negligible cell activation and no pro-inflammatory cytokine
production on RAW 264.7 macrophages 72 h after the end of
the treatment. Both samples were eﬃciently internalized by
the two types of cells and high platinum levels were found in
the cells after Pt(IV)@CNT exposure. Our study shows that
f-MWCNTs are promising nanocarriers to improve the accumu-
lation of a chemotherapeutic drug inside the cells and demon-
strates that the CNT diameter is an important parameter to
consider in the preparation of the complexes. In particular, a
smaller CNT diameter could be advantageous, allowing a
slower drug release inside tumor cells compared to CNTs with
a larger diameter. This behavior could allow the drug to be
retained in tumor cells and exert its function over a longer
period of time. Future studies will include evaluation of the
Pt(IV)@CNT constructs in both sensitive and Pt-resistant cell
lines, to assess whether these nanocarriers are not only
eﬃcient transporters and delivery systems for chemotherapeu-
tics, but they are also able to overcome the cisplatin-associated
resistance due to P-glycoprotein eﬄux pump mechanisms.
Additional in vivo studies in mice will also be necessary to
assess whether S- and L-CNT samples show a diﬀerent biodis-
tribution in tissues and organs. This would be of fundamental
importance in view of a possible application of Pt(IV)@CNTs in
cancer therapy. In fact, besides having diﬀerent diameters, the
two types of nanotubes possess diﬀerent lengths and such a
characteristic is likely responsible for diﬀerent accumulation
in the body.47
Fig. 9 ICP/AES analysis of the cellular platinum content in HeLa (A) and
RAW 264.7 cells (B) exposed to Pt(IV) or to Pt(IV)@CNTs (1 µM) for 6 h.
One-way ANOVA followed by Bonferroni’s post-test was performed to
determine the statistical diﬀerences versus control cells and to compare
the two Pt(IV)@CNT samples with each other and with Pt(IV) (*p < 0.05;
**p < 0.01; ***p < 0.001).
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4. Experimental section
4.1. Materials and characterization
The large diameter MWCNTs (abbreviated hereafter as L-CNT)
were synthesized by Prof. Ramaprabhu (Indian Institute of
Technology, Chennai, India) with a purity >95% and a length
in the range of 200 nm to several microns. The small diameter
MWCNTs (abbreviated hereafter as S-CNT) were provided by
Nanocyl (thin MWCNT 95+ % C purity, Nanocyl 3100, batch
no. 071119, average length of 1.5 µm). TEM was performed
either on a Hitachi H7500 microscope with an accelerating
voltage of 80 kV or on a Hitachi 600 microscope with an accel-
erating voltage of 75 kV. The CNTs were dispersed in a mixture
of deionized water and ethanol (1 : 1) by water bath sonication,
10 µL of the resulting dispersion were deposited onto carbon-
coated copper TEM grids (Formvar/Carbon 300 Mesh; Cu from
Delta Microscopies) and dried at room temperature. The
ImageJ software was used to measure the length and diameter
of CNTs in TEM images. HR-TEM analyses were performed on
a JEOL 2100F TEM/STEM electron microscope operating at 200
kV coupled to EDX. TGA was performed using a TGA Q500 TA
instrument with a ramp of 10 °C min−1 under nitrogen using a
flow rate of 60 mL min−1. ICP/AES analyses were performed on
Agilent 7500ce apparatus. For this purpose, HeLa or RAW
264.7 were seeded in quadruplicate into 6-well plates at a
density of 6 × 105 cells per well and allowed to adhere over-
night prior to exposure to the free drug or to Pt(IV)@CNTs at a
platinum concentration of 1 µM for 6 h. Cells were then
detached as previously described and the cells in the 4 wells
were collected together in a glass vial.
4.2. Cellular cultures
To compare the behavior of the conjugates in non-phagocytic
and phagocytic cells, human cervix cancer cells HeLa and
Abelson murine leukemia virus transformed macrophages
RAW 264.7 were selected, respectively, as common cancer
models to study the anticancer eﬃcacy of Pt(IV)@CNTs and for
the evaluation of their pro-inflammatory eﬀect. Both cell lines
were purchased from ATCC (VA, USA) and were maintained in
RPMI 1640 medium supplemented with 10% heat inactivated
fetal bovine serum (FBS) and 100 U ml−1 gentamycin (with the
addition of 50 µM β-mercaptoethanol and 20 mM HEPES for
RAW 264.7 macrophages) and incubated at 37 °C in humidi-
fied air containing 5% CO2. Media and solutions were pur-
chased from Lonza. When the confluence reached 70–80%,
HeLa or RAW 264.7 cells were washed with phosphate-buﬀered
saline (PBS), detached with trypsin or with SE buﬀer (PBS con-
taining 2 mM EDTA and 2% FBS), respectively, and sub-
cultured every 2–3 days. Prior to CNT exposure, cells were
detached, counted and reseeded in appropriate well size and
density (see each experiment for details) and allowed to adhere
overnight.
4.3. Flow cytometry analysis
4.3.1. Cell viability. The cytotoxicity of Pt(IV)@CNTs
towards human and murine cell lines was evaluated by flow
cytometry. For the first series of experiments, cells were seeded
into 96-well culture plates at a density of 105 cells per well and
allowed to adhere overnight. The cells were then exposed to
our diﬀerent CNT samples at concentrations ranging from 0.5
µM to 10 µM Pt(IV) for 24 h. For the second series of exper-
iments, cells were seeded into 96-well plates at a density of 2 ×
104 cells per well and allowed to adhere overnight. The cells
were then exposed to the conjugates at concentrations ranging
from 0.1 µM to 2 µM Pt(IV) for 6 h before the medium was
renewed with fresh medium and cells were allowed to grow for
further 72 h. In both experiments, the free drug and the empty
CNTs were used as controls and the corresponding MWCNT
concentrations were back-calculated from Pt(IV) loading inside
MWCNTs while DMSO (20%) was used as the cellular death
positive control. After incubation, RAW 264.7 supernatants
were collected and kept at −20 °C for further investigations.
Cells were harvested with SE buﬀer (RAW 264.7) or trypsinized
(HeLa) and stained with both FITC-Annexin V (AnnV; BD Phar-
mingen 556419) and propidium iodide (PI, 0.2 μg ml−1; Sigma-
Aldrich) in a calcium containing buﬀer. The percentage of live
(AnnV−/PI−), early apoptotic (AnnV+/PI−) and late apoptotic/
necrotic (AnnV+/PI+ and AnnV−/PI+) cells was determined by
acquiring at least 15 000 events using a Gallios flow cytometer
(Beckman Coulter, Villepinte, France) and analyzing the data
with FlowJo software.
4.3.2. Cellular activation. Cells were seeded as previously
described for both cellular viability experiments. After incu-
bation with CNTs, cells were detached with SE buﬀer and
stained with PE-Rat anti-Mouse CD86 antibodies (Clone GL1,
BD Pharmingen 553692), prior to flow cytometry acquisition.
Lipopolysaccharide (LPS, 1 μg ml−1) in combination with inter-
feron-γ (IFN-γ, 1 ng ml−1) was used as the cellular activation
positive control. The CD86 associated geomean fluorescence
intensity (GFI) was determined by acquiring at least 15 000
events using the Gallios flow cytometer and analyzing the data
on live cell gated population (AnnV−/PI−) with FlowJo
software.
4.3.3. Cellular uptake. HeLa and RAW 264.7 cells were
seeded into 24-well plates at a density of 2 × 105 cells per
well and allowed to adhere overnight prior to exposure to
10 µg ml−1 of Pt(IV)@CNTs for 6 h. After incubation, cells were
washed twice with PBS, detached with trypsin (HeLa) or with
SE buﬀer (RAW 264.7) and analyzed by flow cytometry. The
mean fluorescence intensity (MFI) of at least 25 000 events
was measured using the Gallios flow cytometer and the data
on live cell gated population were analyzed with FlowJo
software.
4.4. Cytokine determination
RAW 264.7 macrophage supernatants were collected after treat-
ment for the cellular viability experiment and the levels of
murine pro-inflammatory cytokine tumor necrosis factor alpha
(TNF α) and interleukin-6 (IL6) were detected by a double
sandwich ELISA. LPS (1 μg ml−1) in combination with inter-
feron-γ (IFN γ, 1 ng ml−1) was used as the pro-inflammatory
cytokine production positive control. Polyvinyl microtiter
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plates (Falcon) were coated overnight at 4 °C with 50 μl per
well of purified hamster anti-mouse/rat TNF-α (BD Pharmin-
gen 557516) or purified rat anti-mouse IL6 (BD Pharmingen
554400) diluted in 0.05 M carbonate buﬀer, pH 9.6. After
washing with PBS containing 0.05% Tween (PBS-T), a satur-
ation step was performed by adding 100 µl per well of PBS con-
taining 10% FBS for 1 h at 37 °C. After washing with PBS-T,
50 μl per well of culture supernatants or recombinant mouse
TNF (BD Pharmingen 554589) or recombinant mouse IL6 (BD
Pharmingen 554582), diluted in PBS-10% FBS, were added for
2 h at 37 °C. Plates were then washed with PBS-T and 50 μl of
secondary biotin rabbit anti-rat/mouse TNF (BD Pharmingen
557432) or biotin rat anti-mouse IL6 (BD Pharmingen 554402),
diluted in PBS-10% FBS, were added per well and incubated
for 1 h at 37 °C. Plates were washed with PBS-T, and 50 μl of
streptavidin conjugated to horseradish peroxidase diluted in
PBS-10% FBS were added per well. After 30 min incubation at
37 °C, the plates were washed extensively and the enzymatic
reaction, revealing the presence of cytokines in the tested
supernatants, was visualized by adding 75 µl per well of
3,3′,5,5′-tetramethylbenzidine diluted in 0.1 M citrate buﬀer,
pH 5, in the presence of H2O2. The resulting absorbance was
measured at 450 nm after the reaction was stopped with 25 µl
per well of 1 N HCl.
4.5. Transmission electron microscopy
For TEM observations, the cells were seeded into 24-well plates
on glass coverslips at a density of 5 × 105 cells per well and
allowed to adhere overnight prior to exposure to empty or
Pt(IV)@CNTs at a concentration of 10 µg ml−1 (corresponding
to a drug concentration of about 7.5 µM) for 6 or 24 h. The
cells were then washed with PBS and fixed overnight with
2.5% glutaraldehyde diluted in phosphate buﬀer (PB 0.1 M,
pH 7.2). The day after, cells were washed with distilled water
and fixed again with 0.5% aqueous osmium tetraoxide for 1 h
at room temperature. Cells were rinsed extensively with dis-
tilled water and a series of dehydration baths was performed:
twice with 50% ethanol (10 min), once with 70% ethanol
(20 min), once with ethanol 95% (10 min), twice with absolute
ethanol (10 min) and finally twice with propylene oxide (for
10 min each). Samples were then embedded in epoxy resin
Epon (LX 112 Embedding Kit, LADD). Mixtures of propylene
oxide and Epon resin in 2 : 1 (1 h) and 1 : 2 (1 h) ratios and
finally with pure resin (1 h) were added to the samples. On the
last day, the resin was replaced with the fresh one and further
incubated for 3 h. Polymerized blocks with embedded cells
were then prepared by filling gelatin capsules with fresh resin
and placing them upon the glass coverslips on which cells
were grown. The capsules were then polymerized at 60 °C for
48 h, afterwards glass coverslips were removed from the poly-
merized block surface and ultrathin sections (70 nm thick)
were obtained using an ultramicrotome (Leica) with a
diamond knife (DiATOME). The ultrathin sections were then
collected on butvar-coated single-slot copper grids and exam-
ined by TEM (Hitachi H600 or Hitachi H7500).
4.6. Statistical analysis
We present a summary of the data from at least three separate
experiments run in triplicate for each cell line. Data are pre-
sented as ±SEM (Standard Error of the Mean). Statistical ana-
lyses were performed using a two-way ANOVA test or a one-way
ANOVA test in the case of ICP-AES analysis, followed by Bonfer-
roni’s post-test. All p values < 0.05 were considered significant.
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